---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-25-001357"
form_type: "8-K"
ticker: "IMUX"
cik: "0001280776"
company_name: "IMMUNIC, INC."
filed_at: "2025-09-25T23:59:59+00:00"
generated_at: "2026-05-17T05:38:47.096320+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Immunic presents positive vidofludimus calcium data at ECTRIMS, showing disability improvement in progressive MS

## Summary
- Vidofludimus calcium achieved statistically significant 24-week confirmed disability improvement (HR 2.441, p=0.034) in Phase 2 CALLIPER trial in progressive multiple sclerosis.
- Treatment reduced risk of 24-week confirmed disability worsening by 23.8% overall and 33.7% in patients without baseline Gd+ lesions.
- Long-term EMPhASIS open-label extension data showed 92.7% of RRMS patients remained free of 24-week confirmed disability worsening at 144 weeks.
- Preclinical EAE models demonstrated reduced T cell infiltration and increased neuroprotective markers with vidofludimus calcium.
- Data from four poster presentations and one oral presentation highlighted Nurr1 activation as a novel neuroprotective mechanism.

## SEC filing metadata
- accession: 0001193805-25-001357
- form_type: 8-K
- ticker: IMUX
- cik: 0001280776
- company_name: IMMUNIC, INC.
- filed_at: 2025-09-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1280776/000119380525001357/0001193805-25-001357-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1280776/000119380525001357/e664856_8k-immunic.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-25-001357
- JSON: https://secwatch.observer/filing/0001193805-25-001357.json
- Plain text: https://secwatch.observer/filing/0001193805-25-001357.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.